Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration

Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news